Contrasting of Agenus Inc. (AGEN) and Nektar Therapeutics (NASDAQ:NKTR)

Agenus Inc. (NASDAQ:AGEN) and Nektar Therapeutics (NASDAQ:NKTR) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus Inc. 38.69M 12.23 147.18M -1.40 0.00
Nektar Therapeutics 1.25B 5.86 745.70M 3.96 9.25

Table 1 showcases the gross revenue, earnings per share and valuation of Agenus Inc. and Nektar Therapeutics.


Table 2 represents Agenus Inc. (NASDAQ:AGEN) and Nektar Therapeutics (NASDAQ:NKTR)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Agenus Inc. -380.41% 136.2% -110.7%
Nektar Therapeutics 59.66% 78.6% 53.6%

Volatility and Risk

A 2.27 beta means Agenus Inc.’s volatility is 127.00% more than Standard and Poor’s 500’s volatility. Nektar Therapeutics on the other hand, has 2.87 beta which makes it 187.00% more volatile compared to Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of Agenus Inc. are 1.2 and 1.2. Competitively, Nektar Therapeutics has 13.9 and 13.8 for Current and Quick Ratio. Nektar Therapeutics’s better ability to pay short and long-term obligations than Agenus Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Agenus Inc. and Nektar Therapeutics.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agenus Inc. 0 0 0 0.00
Nektar Therapeutics 0 0 3 3.00

Meanwhile, Nektar Therapeutics’s consensus price target is $73.67, while its potential upside is 74.37%.

Insider & Institutional Ownership

Roughly 32.4% of Agenus Inc. shares are owned by institutional investors while 94.2% of Nektar Therapeutics are owned by institutional investors. Insiders owned roughly 0.1% of Agenus Inc.’s shares. On the other hand, insiders owned about 0.9% of Nektar Therapeutics’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agenus Inc. 9.13% 27.05% 32.83% -9.62% -27.35% -19.33%
Nektar Therapeutics -9.23% -3.4% -44.94% -30.86% -33.14% -38.61%

For the past year Agenus Inc. has stronger performance than Nektar Therapeutics


On 9 of the 12 factors Nektar Therapeutics beats Agenus Inc.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The companyÂ’s drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214; and a strategic collaboration with Eli Lilly and Company to develop and commercialize NKTR-358. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.